Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer
WASHINGTON — Treatment with cretostimogene grenadenorepvec, an investigational intravesically delivered oncolytic immunotherapy, achieved high response rates in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG), according to an interim analysis of the phase III BOND-003 trial. Among 66 patients evaluable for efficacy, 75.7% (95% CI 63-85) achieved a complete response (CR) […]
‘Fantastic,’ ‘Terrific’ Results With Oncolytic Virus Combo for Bladder Cancer
CHICAGO — An oncolytic virus therapy combined with pembrolizumab (Keytruda) produced complete responses (CRs) in 85% of patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), a small phase II trial showed. The results showed CRs in 29 of 34 patients with detectable carcinoma in situ (CIS) treated with cretostimogene grenadenorepvec (CG0070) and the PD-1 […]